Denali Therapeutics Inc. - COMMON STOCK (DNLI) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2017 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
DNLI on Nasdaq
Shares outstanding
147,179,178
Price per share
$18.11
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
150,992,112
Total reported value
$2,493,130,825
% of total 13F portfolios
0.01%
Share change
+15,529,781
Value change
+$260,851,971
Number of holders
247
Price from insider filings
$18.11
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Denali Therapeutics Inc. - COMMON STOCK (DNLI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.2% $173,095,065 10,490,610 BlackRock, Inc. 31 Mar 2025
FMR LLC 5.8% $123,948,417 8,536,392 FMR LLC 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 3.9% $82,251,923 5,664,733 Wellington Management Group LLP 30 Jun 2025
Capital Research Global Investors 3.8% $90,373,982 5,477,211 Capital Research Global Investors 31 Dec 2024
BAILLIE GIFFORD & CO 5.6% -23% $31,927,897 -$7,858,384 2,198,891 -20% BAILLIE GIFFORD & CO 30 Jun 2025

As of 31 Dec 2025, 247 institutional investors reported holding 150,992,112 shares of Denali Therapeutics Inc. - COMMON STOCK (DNLI). This represents 103% of the company’s total 147,179,178 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.9% 13,057,890 +8.9% 0% $215,585,764
BlackRock, Inc. 8.6% 12,715,201 +3.5% 0% $209,927,968
BAILLIE GIFFORD & CO 8.4% 12,310,889 +6.2% 0.17% $203,252,777
T. Rowe Price Investment Management, Inc. 4.9% 7,254,132 +29% 0.08% $119,766,000
Temasek Holdings (Private) Ltd 4.8% 7,012,974 +31% 0.37% $115,784,201
STATE STREET CORP 4.3% 6,263,371 +15% 0% $103,408,255
FMR LLC 4.1% 6,097,211 -3.8% 0.01% $100,664,952
NORGES BANK 3.5% 5,119,622 0.01% $84,524,959
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 3.4% 4,983,726 -8.8% 0.02% $82,281,317
PRICE T ROWE ASSOCIATES INC /MD/ 2.7% 3,915,951 -14% 0.01% $64,654,000
GOLDMAN SACHS GROUP INC 2.6% 3,835,803 +77% 0.01% $63,329,108
BAKER BROS. ADVISORS LP 2.5% 3,731,695 0% 0.36% $61,610,284
Capital Research Global Investors 2.5% 3,729,244 -22% 0.01% $61,569,818
ALLIANCEBERNSTEIN L.P. 2.4% 3,557,935 +1.1% 0.02% $58,741,507
GEODE CAPITAL MANAGEMENT, LLC 2.3% 3,458,131 -0.23% 0% $57,104,172
Holocene Advisors, LP 2.1% 3,152,734 +0.54% 0.11% $52,051,638
Crestline Management, LP 1.9% 2,810,732 -18% 87% $46,405,185
Fisher Asset Management, LLC 1.8% 2,589,403 +59% 0.01% $42,751,042
UBS Group AG 1.6% 2,404,704 +19% 0.01% $39,701,663
DIMENSIONAL FUND ADVISORS LP 1.6% 2,374,303 +0.72% 0.01% $39,198,394
Aberdeen Group plc 1.4% 2,032,967 +83% 0.05% $33,564,285
Casdin Capital, LLC 1.3% 1,840,000 +107% 1.9% $30,378,400
Lynx1 Capital Management LP 1.2% 1,738,750 +564% 5.8% $28,706,762
Point72 Asset Management, L.P. 1.2% 1,700,000 -33% 0.04% $28,067,000
PRINCIPAL FINANCIAL GROUP INC 1% 1,524,123 +20% 0.01% $25,163,271

Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 150,992,112 $2,493,130,825 +$260,851,971 $16.51 247
2025 Q3 135,496,675 $1,967,413,218 -$29,612,796 $14.52 236
2025 Q2 137,594,175 $1,925,023,022 +$63,128,608 $13.99 228
2025 Q1 132,874,634 $1,807,534,753 +$50,388,875 $13.60 219
2024 Q4 127,929,251 $2,607,162,085 +$11,750,487 $20.38 222
2024 Q3 126,754,706 $3,691,746,017 +$83,332,107 $29.13 215
2024 Q2 123,900,320 $2,876,933,310 +$81,781,105 $23.22 202
2024 Q1 122,410,671 $2,512,114,129 +$149,691,318 $20.52 208
2023 Q4 115,037,875 $2,465,293,115 +$48,272,802 $21.46 208
2023 Q3 108,753,813 $2,243,639,062 +$15,314,130 $20.63 194
2023 Q2 107,385,972 $3,168,950,262 +$5,897,175 $29.51 198
2023 Q1 108,017,472 $2,487,976,875 +$45,585,839 $23.04 198
2022 Q4 106,059,670 $2,949,511,974 +$353,989,026 $27.81 195
2022 Q3 92,590,614 $2,841,171,715 -$31,157,203 $30.69 192
2022 Q2 92,689,565 $2,727,755,557 +$180,988,868 $29.43 177
2022 Q1 86,720,578 $2,790,606,045 +$40,452,227 $32.17 177
2021 Q4 85,268,721 $3,803,185,901 +$18,535,233 $44.60 204
2021 Q3 82,102,816 $4,142,844,228 +$169,589,833 $50.45 205
2021 Q2 77,780,665 $6,099,806,785 +$34,022,640 $78.44 204
2021 Q1 77,751,278 $4,438,997,286 +$78,721,718 $57.10 213
2020 Q4 66,445,136 $5,564,771,315 +$193,800,989 $83.76 199
2020 Q3 82,769,611 $2,965,793,194 +$14,445,549 $35.83 168
2020 Q2 82,768,394 $2,001,309,869 +$63,425,607 $24.18 142
2020 Q1 80,458,775 $1,408,929,438 +$149,773,734 $17.51 127
2019 Q4 70,860,285 $1,234,391,510 -$9,532,468 $17.42 107
2019 Q3 71,458,501 $1,094,801,327 -$4,573,862 $15.32 112
2019 Q2 63,549,412 $1,319,252,281 +$54,502,235 $20.76 113
2019 Q1 61,057,319 $1,417,761,132 +$44,297,416 $23.22 113
2018 Q4 68,108,281 $1,407,070,297 -$256,309 $20.66 89
2018 Q3 58,053,077 $1,262,045,654 +$108,737,022 $21.74 76
2018 Q2 53,287,730 $812,631,603 +$13,608,742 $15.25 65
2018 Q1 60,832,830 $1,196,651,992 +$60,152,032 $19.69 56
2017 Q4 58,144,510 $909,309,000 +$907,640,000 $15.64 45